Skip to main content

Table 2 Discontinuation and Re-challenges of Adjuvant Trastuzumab Therapy

From: Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer

Treatment

Number of Patients (%)

Initial Treatment

369

Completed planned therapy

263 (71%)

First Discontinuation

106 (29%)

Permanently Discontinued

29 (27%)

First Re-challenge

77 (73%)

Completed therapy

55 (71%)

Second Discontinuation

22 (29%)

Permanently Discontinued

12 (16%)

Second Re-challenge

10 (45.5%)

Completed therapy

9 (90%)

Third Discontinuation

1 (10%)

Permanently Discontinued

1 (10%)

Total Permanently Discontinued

42 (11%)